Key facts
- FlightPath (Drug Discovery)’s last known valuation is $21.0M.
- It has raised $9.7M; the latest was Later Stage VC ($8.1M) in Oct 2024.
- Notable investors include Michigan Rise, Invest Detroit Ventures, Break Off Capital, Ann Arbor SPARK, First In Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for FlightPath (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for FlightPath (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FlightPath (Drug Discovery)
Developer of antibiotic therapies designed to treat pathogen-driven diseases. The company's therapies kill co-infectious bacteria in Lyme disease to limit microbiome damage and treat multiple pathogenic bacteria in both the oral and gut microbiome, enabling patients to get a new treatment to eradicate rare infectious diseases.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2019
- Employees
- 2
- Website
- flightpath.bio/
- Ownership
- Privately Held (backing)
FlightPath (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FlightPath (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FlightPath (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.